Dan Mandell

A Tale of Two Sentiments: JPM 2025 - LifeSciVC By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC “It was the best of times, it was the worst of times…” Another JPM is behind us, and while much of t...

Very nice piece about the duality in biotech currently leading to flat growth in the sector. Hot areas are reaching saturation, while conviction from crossover investors to support early innovation hasn't yet returned. lifescivc.com/2025/01/a-ta...